Next Generation Probiotics for Neutralizing Obesogenic Effects: Taxa Culturing Searching Strategies

Nutrients. 2021 May 12;13(5):1617. doi: 10.3390/nu13051617.

Abstract

The combination of diet, lifestyle, and the exposure to food obesogens categorized into "microbiota disrupting chemicals" (MDC) could determine obesogenic-related dysbiosis and modify the microbiota diversity that impacts on individual health-disease balances, inducing altered pathogenesis phenotypes. Specific, complementary, and combined treatments are needed to face these altered microbial patterns and the specific misbalances triggered. In this sense, searching for next-generation beneficial microbes or next-generation probiotics (NGP) by microbiota culturing, and focusing on their demonstrated, extensive scope and well-defined functions could contribute to counteracting and repairing the effects of obesogens. Therefore, this review presents a perspective through compiling information and key strategies for directed searching and culturing of NGP that could be administered for obesity and endocrine-related dysbiosis by (i) observing the differential abundance of specific microbiota taxa in obesity-related patients and analyzing their functional roles, (ii) developing microbiota-directed strategies for culturing these taxa groups, and (iii) applying the successful compiled criteria from recent NGP clinical studies. New isolated or cultivable microorganisms from healthy gut microbiota specifically related to obesogens' neutralization effects might be used as an NGP single strain or in consortia, both presenting functions and the ability to palliate metabolic-related disorders. Identification of holistic approaches for searching and using potential NGP, key aspects, the bias, gaps, and proposals of solutions are also considered in this review.

Keywords: Endobolome; culturing; dietary obesogens exposure; endocrine pathogenesis; next-generation probiotics; obesity.

Publication types

  • Review

MeSH terms

  • Bacteriological Techniques
  • Bifidobacterium
  • Gastrointestinal Microbiome
  • Humans
  • Lactobacillus
  • Obesity / prevention & control*
  • Probiotics / therapeutic use*